Partnerships
Medical Partnership
Adventist HealthCare
Our first partnership is with Adventist Healthcare and their standalone Aquilino Cancer Center. Sunstone leadership helped design and continues to power the Bill Richards Center for Healing, the site of Sunstone’s first clinical trial.
Pharmaceutical Partners
Academic Partners
Dana-Farber Cancer Institute
Sunstone collaborates with the Dana-Farber Cancer Institute to develop and publish clinical studies. Dr. Yvan Beaussant, a national expert in palliative care and a pioneer researcher in psychedelic-assisted therapy, serves on the faculty of the Dana-Farber Cancer Institute.
Learn More
Sunstone collaborated with Dr. Beaussant on the ACCEPT study, which was designed to glean treatment experience insights from psilocybin study participants. Sunstone helped design, fund, and enroll patients for this study. Sunstone is currently collaborating with Dr. Beaussant to investigate how MDMA-assisted therapy may benefit cancer patients and caregivers in dyadic treatment, and to understand the barriers that therapists in the BIPOC community face in entry to psychedelic therapy training.
Johns Hopkins Center for Psychedelic & Consciousness Research
Johns Hopkins Center for Psychedelic & Consciousness Research and Sunstone collaborate to support a postdoctoral fellow working with Sunstone at the Bill Richards Center for Healing, with a focus on studying psychedelics in cancer patients.
Learn More
Our post-doctoral candidate has written a paper on grief and adverse events, is working on a protocol to explore psychedelics and prolonged grief disorder, and plans to explore the potential use of functional neuroimaging in clinical studies.
The University of Vermont
Sunstone collaborated with Dr. Robert Gramling and his language lab to better understand the psychedelic experience for Sunstone patients, exploring the use of Natural Language Processing on audio and video recordings to measure therapeutic alliance.
Learn More
Dr. Gramling is an expert in palliative care and hospice, with over 70 articles published. He currently serves as the Inaugural Holly and Bob Miller Chair in Palliative Medicine and the Inaugural Chief of the Division of Palliative Medicine in the Department of Family Medicine at the University of Vermont Medical Center.
McGill University
Sunstone Therapies advised McGill University to develop a grant with the Canadian Institutes of Health Research for a study to assess the efficacy, safety, and acceptability of group and individual psilocybin-assisted psychotherapy in end-of-life psychological distress. Sunstone Therapies informed the clinical trial protocol development in collaboration with McGill University.
National Institute of Health (NIH)
Dr. Ann Berger serves as Chief of Pain and Palliative Care at NIH’s research hospital. She recently developed the new innovative NIH-HEALS, which measures psychosocial spiritual healing of individuals with life-threatening and life-challenging situations. Sunstone worked with Dr. Berger to assess the utility of the NIH-HEALS in psychedelic therapy.
Memorial Sloan Kettering Cancer Center
Sunstone collaborated with the Department of Psychiatry and Behavioral Sciences at Memorial Sloan Kettering Cancer Center on a study of cancer patients using psychedelics in conjunction with meaning-centered therapy—designed to diminish feelings of despair associated with cancer and reconnect to life’s meaning in the face of illness. The manuscript from this study is being prepared for publication.
Fellowships
Partner with Us
We are open to partnering with institutions that share a passion for expanding the accessibility and delivery of psychedelic-assisted therapy.